We are live on ! Find out more
KRTX

Karuna Therapeutics, Inc. Common Stock

Delisted

KRTX was delisted on the 15th of March, 2024.

171 hedge funds and large institutions have $3.83B invested in Karuna Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 58 increasing their positions, 52 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 15

33% more funds holding in top 10

Funds holding in top 10: 68 (+2)

24% more call options, than puts

Call options by funds: $8.28M | Put options by funds: $6.7M

22% more capital invested

Capital invested by funds: $3.13B → $3.83B (+$693M)

12% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 52

8% more funds holding

Funds holding: 159171 (+12)

Holders
171
Holders Change
+12
Holders Change %
+7.55%
% of All Funds
2.63%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.12%
New
28
Increased
58
Reduced
52
Closed
15
Calls
$8.28M
Puts
$6.7M
Net Calls
+$1.58M
Net Calls Change
-$1.31M

KRTX Hedge Fund Activity: Q4 2021 in Review

171 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q4 2021, worth a combined $3.83B — up 22% from $3.13B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new KRTX positions and 15 closed out — a net gain of 13 holders — while 58 added to existing stakes and 52 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $36.2M. The largest seller was Logos Global Management, cutting an estimated $20.7M.

  • 171 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q4 2021, up from 159 in Q3 2021.
  • Funds reported $3.83B of Karuna Therapeutics, Inc. Common Stock stock for Q4 2021, up 22% quarter-over-quarter.
  • 28 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q4 2021 and 15 closed out, a net change of +13 holders.
  • The largest Karuna Therapeutics, Inc. Common Stock buyer in Q4 2021 was Victory Capital Management, an estimated $36.2M added.
  • The largest Karuna Therapeutics, Inc. Common Stock seller in Q4 2021 was Logos Global Management, an estimated $20.7M sold.

Based on aggregated 13F filings for Q4 2021.